Clinical Trial Update: Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate plus hydroxyurea for recurrent glioblastoma multiforme was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Gleevec (Imatinib)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Novartis | Conditions: Recurrent Glioblastoma Multiforme (GBM) | Phase 2 | Status: TERMINATED | Results posted: 2011-05-16